Window Graphics & Wraps
Storefront window graphics cover a variety of different advertising materials from custom window decals to perforated vinyl window clings. Attractive window graphics can include lettering, logos, and high-resolution images that reflect your brand and what you have to offer to the public. For more details, visit the website.
https://www.aboutsigns.ca/wind....ow-signage/window-gr
Large Format Digital Printing
We provide large format digital printing services throughout Southwestern Ontario. If you need large format printing Scarborough, Toronto, Hamilton, or any of the nearby areas, we are standing by to help. With professional large format window clings, you can turn your storefront into a powerful marketing tool. For more details, visit the website.
https://www.aboutsigns.ca/digi....tal-printings/large-
Cut Vinyl Graphics Ontario
Perforated window signs are made from high-quality vinyl that has been perforated with tiny holes across the entire surface. You may also see these signs referred to as one-way window decals or stickers. From the outside, the signs appear opaque with bold graphics and text. For more details, visit the website.
https://www.aboutsigns.ca/wind....ow-signage/perforate
Full Truck Wraps
As the name suggests, full wraps cover most of the vehicle. Full wraps are typically applied to the majority of each side and the rear of the vehicle. This includes rear windows and all door panels. Full truck wraps allow for a cohesive high-impact message, which can be compared to a traveling billboard. For more details, visit the website.
https://www.aboutsigns.ca/vehi....cle-graphics/truck-w
Best Vinyl Decals Ontario
Auto decals are signage options for your commercial fleet. Made from durable automotive vinyl, our auto decals can be applied to car and truck bodies and windows. Custom decals and signs differ from full wraps and are suited to when you want just a few logos with lettering on your commercial vehicles. For more details, visit the website.
https://www.aboutsigns.ca/digi....tal-printings/decals
Signage
With more than 20 years of experience in business signs, About Signs Limited is the perfect company for your branding needs. Our design team will take you through the process step-by-step. Even if you only have a general signage concept in mind, we’ll create a design that matches your brand identity. For more details, visit the website.
https://www.aboutsigns.ca/signs/
Signs And Graphics
We are a fully integrated company providing everything from signs and graphics concepts, right through to production and installation. Affordability, quality, and durability are at the core of what we offer. Whether you’re looking to build an ongoing relationship or simply in need of one-off signs and graphics, you can get started with us today for the VIP treatment. For more details, visit the website.
https://www.aboutsigns.ca/about-us/
Commercial digital print
We offer complete vehicle wrap digital printing, but this isn’t always the best approach for every business. If you have company vehicles that could benefit from subtle branding, our custom decals will be ideal. Managing inventory and keeping track of your vehicles is made easier with our digital printing services. For more details, visit the website.
https://www.aboutsigns.ca/digital-printings/
The TCR-based therapy market is projected to grow at an annualized rate of 51%, claims Roots AnalysisGiven the recent approval of a TCR-based therapy, industry stakeholders have initiated several R&D efforts focused on evaluating the potential of such therapy candidates against various disease indications Roots Analysis has announced the addition of “Global TCR-based Therapy Market (2nd Edition), 2022-2035” report to its list of offerings.
Modified T-cell receptor therapy (TCR therapy) is an emerging class of adoptive therapy that employs genetically modified lymphocytes to target specific tumor markers. Growing burden and unaddressed complex treatment needs of cancer patients have paved the way for more effective, safe and versatile alternatives, such as TCR therapies. Driven by Kimmtrak® approval, promising development pipeline and encouraging clinical trial results, the TCR-based therapy market is anticipated to witness significant growth in the mid to long-term
Key Market Insights
Over 190 TCR-based therapies are currently approved / under development
Close to 45% of the aforementioned candidates are being evaluated in clinical trials (phase I and above), while 30% of them are in preclinical stage of development. More than 90% of the therapy candidates, which are being developed to target a range of disease indications, are autologous in nature. Further, NY-ESO-1 and MAGE have emerged as the most popular target antigens.
More than 7,000 patients have been enrolled in nearly 110 clinical trials, worldwide
Clinical research activity, in terms of number of trials registered, is reported to have increased over the last five years. Of the total number of trials, close to 65% are active and still recruiting patients, while close to 26% have already been completed.
Partnership activity within this domain has grown at a CAGR of 27%, between 2015 and 2021
More than 70 agreements have been inked in the last 5 years. Majority of partnership deals signed within this domain were R&D agreements (26%), licensing agreements (21%), and product development and commercialization agreements (16%).
Over 11.2 USD billion has been invested by both private and public investors in this domain, since 2007
Specifically, in 2020 and 2021, industry players raised over USD 2.7 billion. In addition, majority (39%) of the companies primarily received funding through venture capital rounds. Further, around 70% of the total funding instances were reported by players headquartered in the US.
More than 70 patents have been filed / published related to the TCR-based therapies
Close to 85% of the filed / published patents were patent applications, while around 15% were granted patents and others. Of the total granted applications, close to 45% were filed in North America and Europe.
The market is anticipated to grow at a CAGR of 51%, during the period 2022-2035
In 2035, close to 60% of the market revenues are expected to be generated from sales of therapeutics intended for Nasopharyngeal Carcinoma and Multiple Myeloma. Further, therapies targeting for NY-ESO-1 are expected to occupy a larger share (~50%) of the overall market in 2035.
To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/....reports/tcr-based-th
Key Questions Answered
What is the growth rate of TCR-based therapy market?
Which region has the highest growth rate in the TCR-based Therapies market?
Who are the leading industry and non-industry players in this market?
How many players are developing TCR-based Therapies?
Which target indication covers the largest TCR-based therapy market share?
What is the partnership and collaboration trend in the TCR-based therapy domain?
What is the current IP landscape of TCR-based therapies market?
The financial opportunity within the TCR-based therapies market has been analyzed across the following segments:
Target Indication(s)
Nasopharyngeal Carcinoma
Multiple Myeloma
Head and Neck Carcinoma
Sarcoma, Melanoma
Acute Myeloid Leukemia
Lung Cancer
Ovarian Cancer
Merkel Cell Cancer
Target Antigen
NY-ESO-1
EBV
gp100
Others
Key Geographical Regions
North America
Europe
Asia Pacific
Latin America
Middle East and North Africa
Rest of the World
The report features inputs from eminent industry stakeholders, according to whom, T-cell immunotherapies are expected to be the next big step in cancer immunotherapy. The report includes detailed transcripts of discussions held with the following experts:
Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR)
Miguel Forte (Former Chief Operating Officer, TxCell)
The report includes brief profiles of key players (listed below); each profile features an overview of the company, details related to its financial information (if available), details about TCR-based product(s), such as information on type of therapy and current development status, information on technology portfolio (if available), recent developments related to TCR-based therapies and manufacturing capabilities of the players.
Adaptimmune Therapeutics
Alaunos Therapeutics
Bristol Myers Squibb
Cellular Biomedicine Group
Gilead Sciences
GlaxoSmithKline
Immatics
Immunocore
Lion TCR
Takara Bio
Zelluna Immunotherapy
For additional details, please visit https://www.rootsanalysis.com/....reports/tcr-based-th or email sales@rootsanalysis.com
You may also be interested in the following titles:
1. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (6th Edition), 2022- 2035
2. mRNA Therapeutics and mRNA Vaccines Market (2nd Edition), 2022-2035
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
The global cell cytometry market is anticipated to grow at a CAGR of ~10%, till 2035, claims Roots Analysis
In order to accommodate the growing demand for higher accuracy, greater resolution and improved sensitivity in analytical processes, various industry stakeholders are engaged in the development of novel cytometry platforms with advanced features.Roots Analysis has announced the addition of “Global Cell Cytometry Market: Focus on High Throughput Flow Cytometry and Image Cytometry, 2022-2035” report to its list of offerings.
Novel cell cytometry platforms has emerged to be the crucial analytical and visualization tools with applications across various areas, such as immunology, molecular biology, cancer biology and infectious disease monitoring. As a result, developers are currently engaged in the development of technologically advanced cell cytometry platforms that offer better throughput and accuracy.
Key Market Insights
Currently, more than 180 high throughput flow cytometry and image cytometry platforms are available in the market
Majority (92%) of the high throughput flow cytometers are cell analyzers. Of these, ~40% of the devices operate at a throughput rate of 4 to 15 wells per minute. Similarly, majority (~50%) of the image cytometers can operate as both cell analyzers and cell sorters. Of these, 90% of the devices offer qualitative analysis.
Presently, more than 25 developers are engaged in the development of cell cytometers, globally
Notably, around 40% of the developers that offer high throughput flow cytometers are very large players (having more than 5,000 employees). In addition, 45% of the image cytometer developers were established post 2000. Of these, 75% of the players are headquartered in North America.
Partnership activity in the global cell cytometry market has increased at steady rate, between 2017 and 2021
The maximum number of partnerships were established in 2021. Majority of the instances captured in the report were acquisitions and distribution agreements (25%, each). In addition, 75% of the deals have been inked by players headquartered in North America.
180+ USD million has been invested by various private and public investors in this domain, since 2017
Specifically, in 2020, the players raised over USD 125 million. It is worth noting that, majority (around 75%) of the investments were made in the form of venture capital rounds. Interestingly, around 45%of the funding instances were reported by mid-sized players (51 to 500 employees).
Close to 35 global events related to cell cytometry have been organized, since 2018
Majority of the global events related to cell cytometry include webinars (over 40%) and conferences (~35%). It is worth highlighting that the main agenda of these events was to discuss the advantages of novel cell cytometers and their potential applications.
~500 patents have been granted / filed for cell cytometers, since 2020
70% of these were patent applications; Of these, close to 50% of the patents have been filed in 2021. It is worth noting that 45% of the patents related to cell cytometry were filed / granted in China alone, followed by US (~30%).
The overall market is anticipated to grow at a CAGR of ~10%, during the period 2022-2035
North America and Europe are anticipated to capture around 35% of the market share, by 2035. In terms of types of cytometers, the image cytometers are expected to occupy a larger share (more than 55%) of the overall market in 2035.
To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/....reports/cell-cytomet
Key Questions Answered
Who are the leading players engaged in the development of high throughput flow cytometers and image cytometers?
Which are the popular types of cytometers available in the market?
Which partnership models are commonly adopted by stakeholders engaged in this industry?
What are the investment trends and who are the key investors actively engaged in the development and commercialization of cell cytometers?
What are the key agenda items being discussed in various global events / conferences held related to cell cytometry platforms?
How is the current and future market opportunity likely to be distributed across key market segments?
The financial opportunity within the cell cytometry market has been analyzed across the following segments:
Type of Cytometer
High Throughput Flow Cytometer
Image Cytometer
Company Size
Very Small
Small
Mid-sized
Large
Very Large
Key Geographical Regions
North America
Europe
Asia-Pacific
Rest of the World
The research also includes detailed profiles of key players (listed below) engaged in the cell cytometry market; each profile features an overview of the company, recent developments, and an informed future outlook.
Agilent
Beckman Coulter Life Sciences
Becton Dickinson
Bio-Rad
Chemotec
Milkotronic
Nexcelom Bioscinces
Sartorius
Sony Biotechnology
Thermo Fischer Scientific
Union Biometrica
For additional details, please visit https://www.rootsanalysis.com/....reports/cell-cytomet or email sales@rootsanalysis.com
You may also be interested in the following titles:
1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035
2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com